
Clear Gene, Inc. develops molecular diagnostic tests utilizing genomics and machine learning to detect residual solid tumors, particularly in patients with breast cancer. Their key products include MICA Software™, MICA Test Kits, and MICA–Direct™ Kits, which enhance the efficiency and reliability of lab processes for COVID-19 and cancer diagnostics. The company differentiates itself through its innovative approach, combining advanced data science with rigorous molecular biology, and aims to support clinical labs in improving patient outcomes. With a culture that fosters both innovative thinking and methodical product development, Clear Gene is positioned to make significant advancements in the diagnostics market.

Clear Gene, Inc. develops molecular diagnostic tests utilizing genomics and machine learning to detect residual solid tumors, particularly in patients with breast cancer. Their key products include MICA Software™, MICA Test Kits, and MICA–Direct™ Kits, which enhance the efficiency and reliability of lab processes for COVID-19 and cancer diagnostics. The company differentiates itself through its innovative approach, combining advanced data science with rigorous molecular biology, and aims to support clinical labs in improving patient outcomes. With a culture that fosters both innovative thinking and methodical product development, Clear Gene is positioned to make significant advancements in the diagnostics market.
Headquarters: San Carlos, California, United States
Focus: RNA-based molecular diagnostic tests for cancer and COVID-19
Founded: 2012
Company size: 1–10 employees
Last known funding stage: Seed
Molecular diagnostics for detecting residual solid tumors and infectious disease testing (RNA-based assays).
2012
Biotechnology
Profiles list seed-stage funding; specific amounts and dates are obfuscated.
“Investors listed on profiles include Unpopular Ventures, Founders, Inc., and participation from company founders”